Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review

1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Enzon Pharmaceuticals Inc
  • hVIVO Plc
  • Janssen Therapeutics
  • Novartis AG
  • MORE
Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company also has a wide range of pipeline products in various therapeutic areas in different stages of development. Gilead sells its products through marketing subsidiaries and distributors and corporate partners in Europe, the Americas, Asia-Pacific, the Middle East and Africa. The major products of the company include Harvoni, Sovaldi, Truvada, Atripla, Stribild, Epclusa, Genvoya, Complera/Eviplera, Viread and others. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc Key Recent Developments

Mar 12, 2018: Gilead Sciences Announces Senior Management Changes
Mar 05, 2018: Epilepsy Foundation Awards $200,000 at ‘Shark Tank’ Competition for Innovative Products that Aim to Improve Epilepsy Treatment and Care
Feb 28, 2018: Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan
Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL
Feb 22, 2018: Gilead Sciences Announces Senior Management Change

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Enzon Pharmaceuticals Inc
  • hVIVO Plc
  • Janssen Therapeutics
  • Novartis AG
  • MORE
Section 1 - About the Company
  • Gilead Sciences Inc - Key Facts
  • Gilead Sciences Inc - Key Employees
  • Gilead Sciences Inc - Key Employee Biographies
  • Gilead Sciences Inc - Major Products and Services
  • Gilead Sciences Inc - History
  • Gilead Sciences Inc - Company Statement
  • Gilead Sciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Gilead Sciences Inc - Business Description
  • Product Category: Antiviral Products
  • Overview
  • Performance
  • Product Category: Other Products
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Other Countries
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Gilead Sciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Gilead Sciences Inc - Strengths
  • Gilead Sciences Inc - Weaknesses
  • Gilead Sciences Inc - Opportunities
  • Gilead Sciences Inc - Threats
  • Gilead Sciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Gilead Sciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 05, 2018: Epilepsy Foundation Awards $200,000 at ‘Shark Tank’ Competition for Innovative Products that Aim to Improve Epilepsy Treatment and Care
  • Feb 28, 2018: Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan
  • Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL
  • Feb 22, 2018: Gilead Sciences Announces Senior Management Change
  • Feb 19, 2018: Gilead wins reversal in $2.5 billion dispute with Merck
  • Feb 06, 2018: Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results
  • Jan 11, 2018: Adimab Initiates Update on Clinical Progression of Partner Programs
  • Dec 14, 2017: Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
  • Dec 04, 2017: Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States
  • Nov 03, 2017: Abraham Brass receives grant from Gilead for HIV research
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Gilead Sciences Inc, Key Facts
  • Gilead Sciences Inc, Key Employees
  • Gilead Sciences Inc, Key Employee Biographies
  • Gilead Sciences Inc, Major Products and Services
  • Gilead Sciences Inc, History
  • Gilead Sciences Inc, Other Locations
  • Gilead Sciences Inc, Subsidiaries
  • Gilead Sciences Inc, Joint Venture
  • Gilead Sciences Inc, Key Competitors
  • Gilead Sciences Inc, Ratios based on current share price
  • Gilead Sciences Inc, Annual Ratios
  • Gilead Sciences Inc, Annual Ratios
  • Gilead Sciences Inc, Annual Ratios
  • Gilead Sciences Inc, Interim Ratios
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Gilead Sciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Gilead Sciences Inc, Performance Chart (2013 - 2017)
  • Gilead Sciences Inc, Ratio Charts
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Gilead Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Wave 80 Biosciences Inc
  • United Therapeutics Corp
  • Quanta BioDesign Ltd
  • Ocera Therapeutics Inc
  • Novartis AG
  • Merck & Co Inc
  • Janssen Therapeutics
  • Islet Sciences Inc
  • Intercept Pharmaceuticals Inc
  • hVIVO Plc
  • GlaxoSmithKline Plc
  • Enzon Pharmaceuticals Inc
  • Celgene Corp
  • Boehringer Ingelheim GmbH
  • BioVentures Inc
  • Actelion Pharmaceuticals US Inc
  • Abbott Laboratories
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll